Barely Significant
← all excerpts

Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.

Int J Cancer · 2019 · PMC6590181 · PMID 30613959

Europe PMCDOI
1
hedged sentence
0.0068
closest p · 0.1× alpha
0.0068
boldest claim

The sentences

a positive trendp = 0.0068actually significant
At present, the OS data on the first‐line use of osimertinib compared to geifinib or erlotinib is immature, but osimertinib has displayed a positive trend (HR 0.63, 95% CI 0.45–0.88%; p = 0.0068). 44 The efficacy of osimertinib was better than that of first‐generation EGFR‐TKIs in a first‐line setting, this may due to the lower early resistance rate of osimertinib, which delays the emergence of acquired resistance. 34 , 45 , 46 In addition, in contra

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.